Loading...
Docoh

Baxter International (BAX)

Every day, millions of patients and caregivers rely on Baxter's leading portfolio of critical care, nutrition, renal, hospital and surgical products. For more than 85 years, it has been operating at the critical intersection where innovations that save and sustain lives meet the healthcare providers that make it happen. With products, technologies and therapies available in more than 100 countries, Baxter's employees worldwide are now building upon the company's rich heritage of medical breakthroughs to advance the next generation of transformative healthcare innovations.

Company profile

Ticker
BAX
Exchange
Website
CEO
Jose Almeida
Employees
Incorporated
Location
Fiscal year end
SEC CIK
Subsidiaries
Baxter Corporation • Baxter Healthcare Corporation • Baxter Pharmaceutical Solutions LLC • Baxter Sales and Distribution LLC • Cheetah Medical, Inc. • Gambro Renal Products, Inc. • Gambro UF Solutions, Inc. • Hill-Rom Holdings, Inc • Laboratorios Baxter S.A. • Synovis Life Technologies, Inc. ...
IRS number
360781620

BAX stock data

Calendar

28 Apr 22
17 May 22
31 Dec 22
Quarter (USD) Mar 22 Dec 21 Sep 21 Jun 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD) Dec 21 Dec 20 Dec 19 Dec 18
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Cash burn rate (est.) Burn method: Change in cash Burn method: Operating income Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 2.3B 2.3B 2.3B 2.3B 2.3B 2.3B
Cash burn (monthly) 219M 73.92M (no burn) (no burn) (no burn) (no burn)
Cash used (since last report) 340.02M 114.76M n/a n/a n/a n/a
Cash remaining 1.96B 2.18B n/a n/a n/a n/a
Runway (months of cash) 8.9 29.5 n/a n/a n/a n/a

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
10 May 22 David Brent Shafer Common Stock, $1 par value Grant Acquire A No No 0 2,481 0 2,481
10 May 22 Peter M Wilver Common Stock, $1 par value Grant Acquire A No No 0 2,481 0 2,481
3 May 22 Chen Thomas F Common Stock, $1 par value Grant Acquire A No No 0 2,706 0 15,740
84.9% owned by funds/institutions
13F holders Current Prev Q Change
Total holders 1121 1060 +5.8%
Opened positions 152 80 +90.0%
Closed positions 91 98 -7.1%
Increased positions 347 356 -2.5%
Reduced positions 385 382 +0.8%
13F shares Current Prev Q Change
Total value 36.71B 33.87B +8.4%
Total shares 427.62M 420.89M +1.6%
Total puts 2.06M 1.85M +11.7%
Total calls 1.36M 2.2M -38.2%
Total put/call ratio 1.5 0.8 +80.8%
Largest owners Shares Value Change
Wellington Management 49.65M $4.26B -1.8%
BLK Blackrock 40.11M $3.44B +2.6%
Vanguard 38.98M $3.35B +0.1%
MS Morgan Stanley 28.38M $2.44B +1.8%
STT State Street 21.61M $1.86B +3.2%
Generation Investment Management 21.17M $1.82B +2.1%
Veritas Asset Management 12.22M $1.05B +9.9%
Geode Capital Management 8.72M $746.52M +6.6%
AMP Ameriprise Financial 7.1M $609.24M +15.1%
State Farm Mutual Automobile Insurance 6.85M $588.3M 0.0%
Largest transactions Shares Bought/sold Change
Norges Bank 5.55M +5.55M NEW
MCQEF Macquarie 6.68M +4.65M +229.8%
Caisse De Depot Et Placement Du Quebec 4.83M -2.19M -31.2%
Lazard Asset Management 26.76K -2.12M -98.8%
Capital World Investors 1.53M -1.1M -41.8%
Veritas Asset Management 12.22M +1.1M +9.9%
Millennium Management 3.72M +1.06M +40.1%
BLK Blackrock 40.11M +1.03M +2.6%
BMO Bank of Montreal 1.46M -1.02M -41.1%
JPM JPMorgan Chase & Co. 1.42M +935.66K +194.2%

Financial report summary

?
Management Discussion
  • Net income attributable to Baxter stockholders for the three months ended March 31, 2022 totaled $71 million, or $0.14 per diluted share, compared to $298 million, or $0.58 per diluted share, for the three months ended March 31, 2021. The first quarter of 2022 is the first full quarter reflecting Hillrom results of operations after the December 13, 2021 acquisition. Net income for the three months ended March 31, 2022 included special items which decreased net income by $400 million, or $0.79 per diluted share, respectively, as further discussed below. Net income for the three months ended March 31, 2021 included special items which decreased net income by $88 million, or $0.18 per diluted share, as further discussed below.

Content analysis

?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. sophomore Avg
New words: acknowledged, added, admitting, answer, assembled, Back, bariatric, birthing, Build, Canada, cardiology, climate, collection, competitor, compliant, confidence, conflict, constitute, conversion, denying, desire, desist, diagnose, entity, escalation, exceeded, extinguishment, female, field, fiscal, framework, freight, front, frozen, functional, geopolitical, ill, inflation, Inspector, installation, lack, legacy, Linet, Lira, macroeconomic, maternal, nonpublic, nosocomial, Omicron, outbound, parent, peak, pelvic, penalty, Pfizer, physical, pneumonia, political, preceding, precision, preferred, quantify, repaid, review, Russia, screening, sentence, serving, Sherman, situation, skin, specialty, subpoena, therapy, thousand, Turkey, Turkish, Ukraine, variety, video, vision, war, warranty, workforce, Zosyn
Removed: allocating, appeal, applying, approach, assessing, aware, Baxalta, branded, cancer, chemotherapy, closed, combination, Concurrent, conspiracy, cooperate, covering, disaggregation, Division, doxorubicin, Eastern, exercise, existed, expire, extended, finalize, forma, geographical, German, GlaxoSmithKline, grand, improvement, institutional, Irvine, issuance, Johnson, jury, Justice, license, liposomal, managed, manufacturer, matter, medicine, met, moved, nausea, notified, occurred, output, parallel, Pennsylvania, permitted, positive, postponed, prejudice, pro, reallocate, reallocated, reallocation, recast, reduction, referred, region, relationship, relied, requested, restrict, restructure, saline, seeking, Shire, shortage, single, Specifically, TDS, testimony, upfront, voluntary, vomiting, weakening, York

Patents

Utility
Apparatus for Extracorporeal Treatment of Blood and Method for Determining a Parameter Indicative of the Progress of an Extracorporeal Blood Treatment
12 May 22
An apparatus for extracorporeal treatment of blood (1) comprising a treatment unit, a blood withdrawal line, a blood return line, a preparation line and a spent dialysate line.
Utility
System and Method for Extending the Storage Duration of a Rechargeable Battery of an Infusion Pump
12 May 22
A method for extending the storage lifetime of a battery located in a device is disclosed.
Utility
Device and Method for the Delivery of a Thrombin Activated Fibrin Sealant
12 May 22
The invention relates to a dispenser of a sealant for hemostasis comprising a container configured to receive a fibrinogen solution and an activation compartment being situated downstream of the container and comprising a functionalized support to which a coagulation factor, preferably thrombin, is immobilized, such that upon dispensing the fibrinogen solution it passes through the activation compartment, thereby generating and dispensing polymerizing fibrin as a sealant.
Utility
Hollow Fiber Membrane Bundle
12 May 22
The present disclosure relates to bundles of hollow fiber membranes and a process for their production.
Utility
Blood circuit pressure graphical element for medical treatment user interfaces
10 May 22
Graphical user interfaces for use with extracorporeal blood treatment systems may include a blood circuit pressure graphical element.